These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30356327)

  • 1. Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.
    Andrews ES; Perrenoud L; Nowak KL; You Z; Pasch A; Chonchol M; Kendrick J; Jalal D
    PLoS One; 2018; 13(10):e0205831. PubMed ID: 30356327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?
    Figurek A; Spasovski G
    Int Urol Nephrol; 2018 Oct; 50(10):1863-1870. PubMed ID: 30030677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 inhibition, chronic kidney disease-mineral and bone disorder, and physical function
.
    Nowak KL; Hung A; Ikizler TA; Farmer-Bailey H; Salas-Cruz N; Sarkar S; Hoofnagle A; You Z; Chonchol M
    Clin Nephrol; 2017 Sep; 88(9):132-143. PubMed ID: 28699886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.
    Raji YR; Ajayi SO; Adeoye AM; Amodu O; Tayo BO; Salako BL
    Afr Health Sci; 2022 Mar; 22(1):344-351. PubMed ID: 36032486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications.
    Kaur R; Singh R
    Life Sci; 2022 Dec; 311(Pt B):121148. PubMed ID: 36336124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.
    Malhotra R; Katz R; Hoofnagle A; Bostom A; Rifkin DE; Mcbride R; Probstfield J; Block G; Ix JH
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):36-44. PubMed ID: 29208626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interplay between bone and vessels in pediatric CKD: lessons from a single-center study.
    Preka E; Ranchin B; Doyon A; Vierge M; Ginhoux T; Kassai B; Bacchetta J
    Pediatr Nephrol; 2018 Sep; 33(9):1565-1575. PubMed ID: 29872964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Urate Lowering Therapy Using Allopurinol Improves Serum 25 Hydroxy Vitamin D in Stage 3-5 CKD Patients: A Pilot Study.
    Mohammed A; Marie MA; Abdulazim DO; Hassan M; Shaker O; Ayeldeen G; Salem MM; Sharaf El Din UA;
    Nephron; 2021; 145(2):133-136. PubMed ID: 33378761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
    J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International variations in serum PTH and calcium levels and their mortality associations in peritoneal dialysis patients: Results from PDOPPS.
    Nitta K; Bieber B; Karaboyas A; Johnson DW; Kanjanabuch T; Kim YL; Lambie M; Hartman J; Shen JI; Naljayan M; Pecoits-Filho R; Robinson BM; Pisoni RL; Perl J; Kawanishi H
    Perit Dial Int; 2024 Jul; 44(4):275-286. PubMed ID: 38501163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular Function and Uric Acid-Lowering in Stage 3 CKD.
    Jalal DI; Decker E; Perrenoud L; Nowak KL; Bispham N; Mehta T; Smits G; You Z; Seals D; Chonchol M; Johnson RJ
    J Am Soc Nephrol; 2017 Mar; 28(3):943-952. PubMed ID: 27620990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
    Kim CS; Bae EH; Ma SK; Han SH; Lee KB; Lee J; Oh KH; Chae DW; Kim SW;
    J Korean Med Sci; 2017 Feb; 32(2):240-248. PubMed ID: 28049234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial.
    Massart A; Debelle FD; Racapé J; Gervy C; Husson C; Dhaene M; Wissing KM; Nortier JL
    Am J Kidney Dis; 2014 Nov; 64(5):696-705. PubMed ID: 24856872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.
    Pietrzyk B; Wyskida K; Ficek J; Kolonko A; Ficek R; Więcek A; Olszanecka-Glinianowicz M; Chudek J
    Int Urol Nephrol; 2019 Mar; 51(3):519-526. PubMed ID: 30584645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.
    Seifert ME; de las Fuentes L; Rothstein M; Dietzen DJ; Bierhals AJ; Cheng SC; Ross W; Windus D; Dávila-Román VG; Hruska KA
    Am J Nephrol; 2013; 38(2):158-67. PubMed ID: 23941761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.
    Manghat P; Fraser WD; Wierzbicki AS; Fogelman I; Goldsmith DJ; Hampson G
    Osteoporos Int; 2010 Nov; 21(11):1853-61. PubMed ID: 20012018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.
    Parker VJ; Harjes LM; Dembek K; Young GS; Chew DJ; Toribio RE
    J Vet Intern Med; 2017 May; 31(3):791-798. PubMed ID: 28186657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.